Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement ListTip Ranks·Nov 15, 2026 at 11:13 PM02096-1.13%
Weekly Recap | SIMCERE PHARMA -5.54%, two pipeline winsWeekly Review·Nov 14, 2026 at 05:16 AM02096-1.13%
Simcere Pharmaceutical Files Next-Day Return to HKEX Disclosing Share Buyback for CancellationPUBT·Nov 11, 2026 at 10:59 AM02096-1.13%
China Accepts Simcere’s Zemprocitinib Application for Rheumatoid Arthritis ReviewPUBT·Nov 6, 2026 at 04:11 AM02096-1.13%
Simcere Pharma climbs 5% on zeupocitinib dermatology dealMarket Movers·Nov 4, 2026 at 06:16 AM02096-1.13%
Simcere Pharmaceutical Files HKEX Return Disclosing Share Buyback for CancellationPUBT·Nov 3, 2026 at 11:08 AM02096-1.13%
Simcere Pharmaceutical Group Limited (2096) Gets a Buy from UBSbusinessinsider·Oct 31, 2026 at 06:43 AM02096-1.13%
Simcere Pharmaceutical Files HKEX Next Day Disclosure Return on Share Buyback for CancellationPUBT·Oct 23, 2026 at 10:43 AM02096-1.13%
UBS Downgrades UNITED LAB to Neutral; Reiterates SIMCERE PHARMA as Top PickAASTOCKS News·Oct 22, 2026 at 07:45 AM01093-1.12%01177-1.53%
Diverging Paths in Hong Kong Equities: Pharma Deals and AI Drive FundamentalsGlobal Report·Sep 22, 2026 at 10:14 AM00376-3.73%02096-1.13%
Liquidity Diverges Across HK Equities as Tech and Pharma Firms Face ShakeupsGlobal Report·Sep 22, 2026 at 09:19 AM004930.00%00694+4.05%
Inside the HK Market: Infrastructure Dividends, Biotech Moves and Sector OverhaulsGlobal Report·Sep 15, 2026 at 11:33 AM00905+3.57%00368+0.38%